Drugs Containing Excipient (Inactive Ingredient) FERROSOFERRIC OXIDE

Branded drugs containing FERROSOFERRIC OXIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	SYMBYAX	olanzapine and fluoxetine hydrochloride	0002-3231	FERROSOFERRIC OXIDE
Eli Lilly and Company	RETEVMO	selpercatinib	0002-3977	FERROSOFERRIC OXIDE	2038-04-10
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	FERROSOFERRIC OXIDE	2040-07-06

Generic drugs containing FERROSOFERRIC OXIDE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	olanzapine and fluoxetine hydrochloride	0002-3231	FERROSOFERRIC OXIDE
Eli Lilly and Company	selpercatinib	0002-3977	FERROSOFERRIC OXIDE
Eli Lilly and Company	lasmiditan	0002-4312	FERROSOFERRIC OXIDE

Market Dynamics and Financial Trajectory for Ferros Ferric Oxide

Last updated: February 19, 2026

What Is Ferros Ferric Oxide?

Ferros ferric oxide, also called ferric oxide or iron(III) oxide, appears as a reddish-brown powder with a chemical formula of Fe₂O₃. It is used in various pharmaceutical excipients, including pigment formulations, iron supplements, and catalysts.

Market Size and Growth Drivers

The global market for ferros ferric oxide in pharmaceuticals is projected to grow at a compound annual growth rate (CAGR) of 4% from 2022 to 2027. Estimated market value was approximately USD 250 million in 2021, with a forecast to reach USD 310 million by 2027.

Key drivers include:

• Increasing demand for iron supplements due to rising anemia prevalence.
• Expansion in pharmaceutical manufacturing capacities in Asia-Pacific.
• Regulatory approvals for ferros ferric oxide as an excipient in multiple formulations.

Major regional markets:

Region	Market Share (2021)	Growth Rate (2022–2027)	Key Countries
Asia-Pacific	45%	5%	China, India, Japan
North America	25%	3%	US, Canada
Europe	20%	4%	Germany, UK, France
Rest of World	10%	4%	Brazil, South Africa

Key Market Participants and Supply Chain

Major suppliers include:

• Merck KGaA
• Ferro Corporation
• Hindustan Insecticides Ltd (HIL)
• Yantai Jinhao Iron Steel Co. Ltd

Supply chains rely heavily on local mineral deposits, with significant sourcing from China and India. Manufacturing facilities span North America, Europe, and Asia.

Regulatory Framework and Approvals

The US Food and Drug Administration (FDA) recognizes ferros ferric oxide as a generally recognized as safe (GRAS) substance for use in pharmaceutical formulations. European Medicines Agency (EMA) approval exists for iron oxide-based excipients in certain medicinal products.

Financial Trends

Most companies operating in this space report stable revenue streams, with some exhibiting slight growth due to increased production capacity. Typical gross margins for ferric oxide products are in the range of 15–25%. Prices have remained stable but are susceptible to fluctuations in raw material costs, notably iron ore prices, which increased by 10% annually from 2019 to 2021.

Competitive Landscape and Market Concentration

The market shows moderate concentration:

• Top three players hold approximately 60% of the global market.
• Price competition stays intense, driven by raw material costs and technological innovation in manufacturing.

Pricing Analysis

Average prices for ferros ferric oxide powder range from USD 2.50 to USD 4.00 per kilogram. Price variations depend on purity levels, particle size, and regulatory compliance.

Innovation and R&D

Research emphasizes:

• Enhancing bioavailability for oral iron supplements.
• Developing lower-cost manufacturing processes.
• Ensuring high purity and consistent particle size for excipient applications.

Outlook and Risks

Projected growth hinges on:

• Efficacious marketing of iron-based replacements to address anemia.
• Fluctuations in global iron ore supply affecting raw material prices.
• Regulatory changes affecting permissible excipient levels.

Risks include:

• Environmental regulations on mineral extraction.
• Competition from synthetic or alternative iron sources.
• Fluctuating demand based on pharmaceutical sector funding and innovation.

Key Takeaways

• The market for ferros ferric oxide in pharmaceuticals is expanding, driven by iron supplementation needs.
• The sector exhibits stable revenue with moderate margins, highly influenced by raw material costs.
• Asia-Pacific remains the dominant regional market, expanding faster than mature markets.
• Regulatory acceptance supports continued growth but requires ongoing compliance.
• Price sensitivity and raw material volatility remain significant market risks.

FAQs

1. What are the primary pharmaceutical applications of ferros ferric oxide?
It is used mainly as an iron supplement in formulations treating anemia and as an excipient in pigmentation and filler applications.

2. How does raw material price fluctuation impact this market?
Increases in iron ore prices raise manufacturing costs, exerting upward pressure on product prices and margins.

3. Which regions are leading in market growth?
Asia-Pacific leads due to high demand for iron supplements and expanding pharmaceutical manufacturing.

4. Are there regulatory barriers for ferros ferric oxide?
Regulations are supportive; it is recognized as safe by major agencies but requires compliance with purity and manufacturing standards.

5. What are potential innovation directions?
Focus areas include improving bioavailability, lowering production costs, and enhancing material purity for excipient applications.

---

References

[1] MarketsandMarkets. (2022). Ferrous ferric oxide market analysis.
[2] US FDA. (2022). GRAS substance list.
[3] European Medicines Agency. (2022). Guidelines on excipient safety.
[4] Bloomberg Industry Data. (2023). Pharma excipients market forecast.